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The distribution of peripheral blood T cells bearing Fc 
receptors for IgG (Ty) and IgM (TJ.I) was determined in 
18 patients with cutaneous T-cell lymphoma (Sezary 
syndrome, mycosis fungoides) and 15 normal controls. 
The mean percent of TJ.I and Ty cells in the patients with 
morphologically normal lymphocytes was similar to that 
of the control subjects. In 13 patients with circulating 
malignant cells representing 30-100% of their peripheral 
blood lymphocytes, the mean percentages of TJ.I and Ty 
were low. In 9 patients the majority of the malignant T 
cells did not exhibit Fc receptors for IgG or IgM. In some 
patients, however, high blood lymphocyte counts re-
sulted in normal or high concentrations of all the T-cell 
subsets. Further, in 4 patients, lymphocytes with the 
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characteristic nuclear abnormalities of "Sezary /my-
cosis" cells were found in both the TJ.I and Ty, as well as 
the TnonynonJ.l, subpopulations. The heterogeneity of the 
Fc receptors on cutaneous T-cell lymphoma lymphocytes 
suggests that these receptors are not useful as clonal 
markers in these disorders. 
The term cutaneous T-cell lymphoma (CTCL) describes a 
spectrum of malignant Iymphoproliferative disorders primarily 
involving the skin that includes mycosis fungoides and the 
Sezary syndrome [I). The Sezary syndrome is characterized by 
an exfoliative erythroderma, generalized lymphadenopathy, 
and circulating abnormal lymphocytes. Approximately 20-40% 
of patients with mycosis fungoides also have peripheral blood 
involvement demonstrable by light and electron microscopy [2-
4). The abnormal cell (the CTCL or "Seuuy/mycosis" cell) is 
a lymphocyte of variable size with a high nuclear to cytoplasmic 
ratio, characteristic convoluted or cerebriform nuclear contours, 
and often dense nuclear chromatin. These cells usually display 
properties of T cells in that they form rosettes with sheep red 
blood cells (SRBC) , react with anti-T-cell antisera, and are 
found in the paracortical areas of involved lymph nodes [5-7]. 
Recently, subpopulations of T cells have been described 
which possess receptors for the Fc portion of IgG (Ty cells) and 
IgM (TJ.I cells) [8-10]. Early studies of isolated subpopulations 
presented evidence that TJ.L cells were able to provide help to 
polyconal B cell differentiation induced by pokeweed mitogen 
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(PWM) and that Ty cells, after exposure to IgG, functioned as 
suppressor celis in this system [11). 
The study of T-cell subpopulations in CTCL is of special 
interest because of the in vitro demonstration of helper activity 
by leukemic 'I' cells from patients with the Sezary syndrome 
[12,13] and by neoplastic lymph node 'I' cells from patients with 
mycosis fungoides [14). A patient with the Sezary synru'ome 
has also been described whose malignant 'I' lymphocytes sup-
pressed immunoglobulin synthesis by B lymphocytes [15). 
These data suggested that the malignant cell in most patients 
with Sezary syndrome might have its origin in a 'I' cell having 
exclusive ' helper function and carrying surface receptors for 
IgM. More rarely a malignant transformation might occur in a 
'I' cell having suppressor function and surface receptors for IgG. 
The results of our study of leukemic cells from patients with 
CTCL, however, show that the majority of cells in most patients 
generaliy do not exhibit Fc receptors for IgM or IgG. Further-
more in certain patients malignant cells can be demonstrated 
in both the 'I'll and Ty subpoulations as well, indicating that Fc 
receptors are not useful for the identification of a neoplastic 
clone ofT cells in this disorder. 
MATERIALS AND METHODS 
Eighteen patients with histologically conClrmed CTCL were studied. 
Sixteen patients had extensive skin disease and extracutaneous spread 
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in the form of biopsy-proved lymph node or peripheral blood inflltra-
tion. One patient had limited plaque skin disease involving less than 
10% of t he skin surface. The characteristics of the 18 patients, including 
t he type of skin involvement, the absolu te lymphocyte count, and 
lymphocyte morphology are shown in Table I. T hirteen patien ts (group 
A) had peripheral blood involvement as judged by the presence of 30-
100% lymphocytes with convoluted nucle i typical of Sezary / mycosis or 
CT CL ceLIs on periphera l blood smear. Seven of these patients had 
elevated absolu te lymphocyte concentrations (4,900/fLl-123,000/ fLl); 
the remaining pa tients had normal or low lymphocyte counts. Five 
patients (group B) had morphologically normal lymphocytes by ligh t 
and electron microscopy. T he percentage of circulating monocytes 
ranged [Tom 0-10% (median 3%) in group A and 4-20% (median 14%) in 
group B. 
All but 5 patients (Table 1) had received trea tment with whole- body 
electron-beam radiotherapy and chemotherapy as described previous ly 
[17]. Elapsed time since prior chemotherapy varied from 1 to 428 days 
with a median of 22 days. Fifteen healthy hospital personnel ranging in 
age from 25 to 58 served as control subjects. The study was approved 
by t he H uman S tudies Subcommittee of the Research and Education 
Committee of t his hospital. 
Lymphocyte Subpopulation.8 
T lymphocytes were iden tified by their ability to form spontaneous 
rosettes with 2-aminoethylisothiouronium bromide (AET)-treated 
SRBC [18, 19]. B cells were determined by the presence of membrane 
immunoglobulin [20] and receptors for C3 [21]. 
For T -cell enrichment, mononuclear cells were isolated on a Hy-
T ABLE 1. Lymphocyte populations in 18 patients with cutaneous T -cell lymphoma 
Patients Type of skin Lymphocytes Convolu ted T Ty 'I'll 'l 'no llynon,u Prior therapy/ involvement per ILl lymphocytes" % % % % 
Group A 
1 49M Erythroderma 123,000 100 49 2 11 87 Steroids 
2 68F Erythroderma 47,000 100 60 3 18 79 Leukapheresis 
3 62F Erythroderma 16,000 90 72 6 61 33 EBRT, CRx (daily) 
4 60M Erythroderma 6,000 50 14 9 24 66 EBRT, CRx (30 days) 
5 75F Erythroderma 7,000 90 40 4 11 85 EBRT, CRx (72 days) 
6 56M E rythroderma 6,000 60 79 3 14 83 EBRT, CRx (35 days) 
7 48M Erythroderma 5,400 95 71 3 13 84 None 
8 48F Erythroderma 1,700 45 83 11 19 70 EBRT, CRx (2 days) 
9 45F· Erythroderma 2,500 80 84 10 41 49 EBRT, CRx (7 days) 
10 63M E rythroderma 1,800 50 88 11 63 26 EBHT, CRx (60 days) 
11 66M Erythl'oderma 1,800 30 68 14 36 50 EBRT, CRx (472 days) 
12 30M T umor d'emblee 2,000 70 85 18 EBHT, CRx (22 days) 
13 67F Generalized 1,000 45 86 20 22 58 None 
plaque/tumor 
Group B 
1 49F General ized 2,100 Normal 86 78 EBRT, CRx (7 days) 
plaque/tumor 
2 55F Generalized 1,700 Normal 86 23 16 61 EBRT, CRx (7 days) 
plaque/tumor 
3 71M Generalized 1,100 Normal - c 41 EBRT, CRx (10 daylj) 
plaque/tumor 
4 68M Generalized 1,600 Normal 80 10 35 55 EBRT, CRx (90 days) 
plaque/tumor 
5 42M Limited plaque 2,300 Normal 76 16 56 28 None 
GrottpA 
N = 13 Mean 68 8 27 64 
(SD) (22) (6) (18) (21) 
p" NS < 0.01 < 0.001 < 0.001 
Group B 82 16 45 48 
N = 5 (5) (7) (23) (18) 
p" NS NS NS NS 
Healthy con- 79 17 57 28 
trols (3 ) (8) (8) (10) 
N = 15 
"The percent lymphocytes with convolu ted 0 1' grooved nuclei ("Sezary/mycosis" cells) found in Wright-Giemsa stained peripheral blood 
smears (16). 
/, EBRT refers to electron-beam radiotherapy; CRx, chemotherapy. The time in parentheses refers to the time the patient lasl·. received 
chemotherapy. Three patien ts (A 1.2, B1, and B2) were receiving weekly EBRT treatments to the skin at the time of study, the remainder had 
completed EBRT 5 to 27 months earlier. 
,. The percentages of Ty in these 3 patients were between 19-24%; however rosetted monocytes were noted in the cytocentrifuge preparations 
and therefore the results have been d iscounted. 
" p value for comparison of group A and con trols. 
, p value for comparison by group B and controls. 
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paque-Ficoll density gradient [22] and depleted of adherent cells until 
less than 2% monocytes remained as determined by light microscopy of 
wet preparations. Prior to the incubation of mononuclear cells on 
plastic Petri dishes at 37°C for 1 hr, the percentage of monocytes in the 
patients ranged from 1-28% (median 5%, mean 6.6%). The T lympho-
cytes were lhen sepru·ated from non-T cell by roselte formation with 
AET-treated SHBC followed by centrifugation on a Hypaque-FicoLl 
density gradient at 4°C [23). The resulting pellet contained 93-99% 
rosetted lymphocytes and no more than 1% B cells. SRBC attached to 
the lymphocytes were lysed using 0.85% ammonium chloride buffer 
with EDTA and washed with RPM I 1640 medium. 
Prepara.tion of Ox R ed Cell·Antibody (OXEA) Complexes 
IgG and IgM fractions of rabbi t anti-ox red cell antibody were 
obta ined from Cappel Laboratories (Cochranville, Pennsylvania). In 
addition, IgG was purified by DEAE-cellulose cl1J"omatography and 
Sephru·ose G-200 gel fil tration fTom sera raised in rabbits by intravenous 
injectivn of ox red blood cells. A modification of the method described 
by Moretta et al [9,10] was used to prepare OXEA complexes and to 
determine Ty and Til subpopulations. For the OX7~EA complex, a 5% 
suspension of washed ox red cells was incubated with a nonhemagglu-
t inating dilulion of IgG antibody for 15 min at 30°C, washed wi th 
phosphate-buffered saline (PBS) , and resuspended to a concentration 
of 2.5%. To prepare OX19sEA complexes, a 2% suspension of ox red 
cells was incubated with the IgM antibody for 30 min on ice, washed 
with PBS, and resuspended to a concentration of 0.5% 
As.says for T Cells B earillg Receptors for [gM (7'J.L) an.d for [gO (Ty) 
Til assay: Aliquots of 1 X 10" ceLls/ml from the T-cell-emiched 
frac tion were incubated overnight in 20% fetal calf serum (Flow Labo-
ratories, Hockville, Maryland) at 37°C in a 5% CO. incubator. The 
fo llowing day, cells were washed and resuspended in TC-199 medium 
to a concentration of 3 X 10';/ ml; 0.1 ml of lhe suspension was then 
mixed with O. lml of the OX19"EA reagent and centrifuged at 4°C for 
5 min at 300 g . After 45-min incubation on ice 200 cells were counted 
to determine the percentages of rosetted lymphocytes. A rosette was 
defined as a lymphocyte binding 3 or more ox red cells. 
T y assay: One-tenth millili ter of the T-ceU-e/ll"iched fnlction (3 x 
10"/ml) was mixed wi th 0.1 ml of Ox7sEA reagent, centrifuged at 300 g 
for 5 min at 4°C, and lei stand at room temperature for 30 min before 
counting as above. . 
Cyiocenirifuge preparations were made from T, Ty, and Til cell 
suspensions and stained with Wright-G iemsa for morphologic exami-
nation of rosetted lymphocytes. In 3 Iymphopenic patients, rosetted 
monocytes were observed in the Ty cyiocentrifuge prepru·ations; there-
fore in lhese cases the Ty percentage determined fro m the wet prepa-
rations was discounted since it was considered to be inflated by the 
monocyte rosettes. Hosetted monocytes were not observed in the T~I 
preparations. 
Statistical Methods 
Student's t-iest and the rank sum tesi were used to compru·e the 
diffe rences between the patient and control groups. 
RESULTS 
The results of sw-face marker studies of the peripheral blood 
lymphocytes of the patients and controls ar e shown in T able 1. 
There was no significant difference between the percentages of 
T cells of either patient group and the control group. However, 
3 patients with erythroderma who had elevated nW11bers of 
circulating convoluted (Sezary/mycosis) lymphocytes (patients 
1, 4, and 5) had low percentages ofT cells (14%, 40%, 49%). The 
abnormal lymphocytes of pa tient 4 had shown a progressive 
decrease in the ability to bind SRBC from 79% to 14% over the 
preceding 2 years. 
The mean percentages of T y (8 ± 5 S .D.) and T/-t cells (27 ± 
18 S.D.) in the patients with circulating Sezary/mycosis cells 
(group A) were significantly different (Tom those of t he control 
subjects (Ty 17 ~ 8, T/-t 57 ± 8) which resulted in a higher 
calculated percentage of Tnonynon~1 cells in the group A pa-
tients (Table I) . Only 1 of the 5 patients with morphologically 
normal lymphocytes (group B) had less than 25% TJ.L cells, 
whereas 9 of the 13 group A patients had markedly low per-
centages of T/-t cells (11 -24%). In these 9 patients the majority 
of the ci.rculating T cells (most of which were morphologically 
CUTAN EOUS T-CELL LYMPHOMA: T-CELL SUBSETS 319 
consistent with Sezary/ mycosis cells) did not exhibit Fc recep-
tors for IgG or IgM. 
The median absolute blood concentrations (circulating cells/ 
pl) of lymphocytes, T cells, and Ty cells of the patient groups 
and the control subj ects were not significantly different. Al-
though the median concentration of T/-t cells was lower and 
Tnonynon/-t cells was higher in the group A patients as com-
pared to the control subjects, these differences were not statis-
tically significant by the rank sum test. In most of the patients 
a low percentage of T/-t or Ty cells meant low circulating 
concentrations. However 3 patients had elevated absolute con-
centrations of T/-t (5,000-1O,000/ /-t1) and Ty (700-2,000/ /-t1) cells, 
despite low percen tages in 2 patients, due to marked peripheral 
blood lymphocytosis. 
The }·ole of previous th erapy in altering the distributions of 
T/-t and T y in these patients was examined. Fow- of t he 10 
patients with very low percentages of T/-t cells « 25%) had 
received neither electron-beam nor systemic chemotherapy. 
One of these patients was studied on 3 occasions over a 5-month 
period and showed persistently low percentages of T/-t (15%, 
18%, and 13%). The r emaining 6 patients had received therapy 
similar to the patients with higher pel·centages of T,u cells 
(Table I) . Two ofthese patients were also restudied after a 3-5 
month period and showed no chan ge or a further fall in the 
percentage of T,u cells. 
The Wright-Giemsa stain ed cytocentrifuge smears of the T,u 
and Ty preparations generally showed lower percentages of 
rosetted cells than t hose noted in the wet preparations, indicat-
ing t he instability of the rosettes. All of the T,u rosettes in the 
preparations from the group B and some from the gJ"Oup A 
patients conta ined lymphocytes with nuclei of normal appear-
ance. In 8 of the group A patients the quality of the cytocentri-
fu ge preparations allowed the identificatiion of cells with the 
distinctive nuclear morphology of CTCL cells in the center of 
the T,u rosettes, indicating that at least a fraction of th e malig-
nant cells had membrane receptors for IgM (Fig lA). While 
most of the Ty rosettes fTom both group A and group B patients 
contained ly mphocytes of normal appearance, 4 group A pa-
t ients (#2, 3, 4, 9) had typical convoluted CTCL cells rosetted 
with IgG-coated ox cells (Fig 1B), indicating that malignant 
cells could be found in the Ty as well as the T,u and the 
Tnonynon~L subpopulations. 
DISCUSSION 
Previous studies of the Fc receptors on T cells in CTCL have 
yielded variable results. Worman et al [24] reported that the 
leukemic cells of 2 patients with the Sezary syndrome were 
composed of predominan t ly T,u cells. However Gupta et al [25] 
found differing distributions of these T-cell subsets in 3 patients 
with the Sezary syndrome, including one patient lacking Ty 
cells, a second lacking both Ty and T,u cells, and a third with a 
normal proportion of T,u cells and a high percentage of Ty cells. 
The results of om study present further evidence that pe-
ripheral blood lymphocytes in patients with advanced CTCL 
display heterogeneity with regard to T,u and Ty subpopulations. 
The predominant T-cell subpopulation in most patients with 
circulating CTCL cells with respect to both percentage and 
concentration appears to be the Tnonynon,u population. In only 
2 patients out of 6 with greater than 80% malignant cells was 
the T/-t percentage normal or near normal, indicating that a 
moderate proport ion of malignant cells bore Fc receptors for 
IgM. None of the group A patients demonstrated elevated 
proportions of Ty cells similar to the severely lymphopenic 
patient with the Sezary syndrome reported by Gupta et al 
[25]. However, when Ou)" data were examined in terms of 
circulating cell concentrations, we found that patients with 
marked lymphocytosis had expanded pools of all the T-cell 
subsets despite low percentages of Ty and/ or T,u cells. 
In the majority of the gr oup A patients, at least a fraction of 
the malignant cells had receptors for IgM as shown by the 
Wright-Giemsa. stained cytocentr ifuge preparations. In 4 group 
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FIG 1. CTCL ("Sezary/mycosis") cells from a patient exhibiting Fc 
receptors for Ig,M and IgG. A, Rosetted with OX19sEA (T/i cell). B, 
Rosetted with OX7sEA (Ty cell). x 1600. 
A patients, a small number of typical CTCL cells was also found 
in the Ty as well as the TJ.! and TnonynonJ.! populations. 
Therefore it would appear that in most instances the CTCL cell 
does not represent a malignant clone derived specifically from 
either the TJ.! or the Ty subpopulation . 
Normal T lymphocytes may have contributed to the rosetting 
in some of the patients with circulating malignant cells; how-
ever, this contribution appeared to be small as most of these 
patients had high proportions of morphologically abnormal 
cells. In patients with normal-appearing peripheral blood lym-
phocytes it is likely that most of the lymphocytes tested were 
not malignant. This is reflected in the normal or near-normal 
percentages in the group B patients and the normal appearance 
of the rosetted lymphocytes in the cytocentrifuge preparations. 
Gupta et al [25] reported elevated proportions of Ty cells in 
3 of 11 patients with mycosis fungoides and nQrmal-appearing 
lymphocytes. However it is not clear whether possible contam-
ination by monocytes was ruled out in these patients' Ty 
preparatIOns. It has recently been appreciated that varying 
proportions of Ty cells may react with a monoclonal antibody 
having antimonocyte specificity [26]. In our own studies we 
. have appreciated that in severely lymphopenic patients, high 
monocyte to lymphocyte ratios may result in significant mono-
cyte contamination despite adherence or phagocytosis tech-
niques to remove them. 
One .of our patients with mycosis fungoides and morphologi-
cally normal circulating lymphocytes did have markedly low 
TJ.! cells. Cytogenetic studies. have shown that small numbers of 
malignant cells may circulate and go unrecognized by light 
microscopy [27]. The role that this phenomenon may play in 
the alteration of the proportions of the T-cell subpopulations in 
these patients is unclear. 
It is possible that therapy influenced the expression of the Fc 
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receptor as it has been shown that agents such as radiation and 
corticosteroids can affect proportions of TJ.! and Ty cells [28]. 
However, in our patients there appeared to be no consistent 
relationship between qualitative or quantitative aspects ofther-
apy and proportions of T cell subpopulations. 
The significance of the increase in the TnonynonJ.! subpopu-
lation of cells is pUTely speculative. A certain percentage of 
these cells might be expected to have receptors for other 
immunolobulins such as IgA (Ta) or IgE (Te) [29,30]. On the 
other hand, failure in membrane differentiation associated with 
malignant transformation or activation of the cell by immune 
complexes [31] could have occUTred, resulting in the absence or 
loss of the receptor. Activated lymphocytes such as the atypical 
lymphocytes in infectious mononucleosis have been shown to 
lack detectable Fc receptors [32]. Alternatively, this population 
of cells may be in a state of transition between Fc positive 
states (Ty-+TJ.!) as suggested by Pichler et al [33]. 
Recent studies have suggested that the relationship of 
T -lymphocyte Fc receptors to the capacity of the cell to act as 
a helper or suppressor may be extremely complex. Haywood et 
al [34] demonstrated that isolated TJ.! cells stimulated with 
concanavalin A could suppress the PWM-induced differentia-
tion of B cells, concluding that the TJ.! subpopulation may not 
be restricted to helper activity. Pichler et al [33] have shown 
that under certain conditions, isolated Ty cells can later dem-
onstrate the surface receptor for IgM, raising the possibility 
that subsets of T cells may express each receptor at different 
stages or even express both receptors simultaneously. Therefore 
our findings of heterogeneous expression of the Fc receptor on 
T cells of patients with CTCL are not necessarily at variance 
with the demonstration of a predominantly helper function by 
these cells in vitro . However, the Fc receptor would seem to be 
of questionable use in the identification of a clone of helper T 
cells in CTCL. Studies recently reported [35,36] using monoclo-
nal antibodies indicate that these reagents have provided a 
more useful tool to distinguish the subsets of T lymphocytes 
from which CTCL cells originate, and confirm the previous 
findings that these cells appear to derive from the T helper 
lineage. 
The authors are indebted to the excellent technical assistance of 
Miss Frances Soehnlen and to Dr. Elaine Jaffe for her helpfu l review 
of the manuscript. 
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Extracellular Granular Material and Degeneration of Keratinocytes in the 
Normally Pigmented Epidermis of Patients with Vitiligo* 
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Multiple biopsy specimens from the skin of 28 patients 
with common vitiligo were examined by light and elec-
tron microscopy. The patients were grouped according 
to the activity of their disease : progressing, s table, r e-
pigmenting, and r esistant to treatment with psoralen 
plus s unlight. Tlu'ee biopsy sites w er e sampled from each 
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In tercellular particulate material a nd degeneration of keratinocytes in 
patient: (W) a white spot; (1) the pigmented and white 
interface ; and (P) normally pigmen ted skin 1-15 em 
away from I. Control specimens w er e obtained from 17 
persons without vitiligo, 
Two microscopic abnormalit ies wer e observed in th e 
epidermis of th e patients with vitiligo: deposits of extr a -
the clinically norma l epidermis of patients wi th vitiligo. J Invest Der-
matol 76:321, 1981. 
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Abbreviations: 
EGM : extracellular gr anular material 
PUV A: psora len plus rutificial ultraviolet A 
